Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Mary Kate Hart"'
Autor:
Paul W Fenimore, Majidat A Muhammad, William M Fischer, Brian T Foley, Russell R Bakken, James R Thurmond, Karina Yusim, Hyejin Yoon, Michael Parker, Mary Kate Hart, John M Dye, Bette Korber, Carla Kuiken
Publikováno v:
PLoS ONE, Vol 7, Iss 10, p e44769 (2012)
We report the rational design and in vivo testing of mosaic proteins for a polyvalent pan-filoviral vaccine using a computational strategy designed for the Human Immunodeficiency Virus type 1 (HIV-1) but also appropriate for Hepatitis C virus (HCV) a
Externí odkaz:
https://doaj.org/article/dad067caf3604da993bc5c6b4a7606b3
Publikováno v:
Emerging Infectious Diseases, Vol 8, Iss 1, Pp 94-96 (2002)
Mycoplasma contamination of the licensed anthrax vaccine administered to military personnel has been suggested as a possible cause of Persian Gulf illness. Vaccine samples tested by nonmilitary laboratories were negative for viable mycoplasma and myc
Externí odkaz:
https://doaj.org/article/758f017b82fe461f842210f072e23ade
Autor:
Hank Lockman, P.F. Fellows, Roy E. Barnewall, Mary Kate Hart, Shannon S. Martin, Karen Metcalfe, Robert Krile, Jessica Price
Publikováno v:
Clinical and Vaccine Immunology. 22:1070-1078
The efficacy of a recombinant plague vaccine (rF1V) was evaluated in cynomolgus macaques (CMs) to establish the relationship among vaccine doses, antibody titers, and survival following an aerosol challenge with a lethal dose of Yersinia pestis strai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b66a9f5349fb4e0883717a1b58db1c7
https://doi.org/10.1128/cvi.00290-15
https://doi.org/10.1128/cvi.00290-15
Autor:
Mary Kate Hart, Wael El-Amin, Sandor Fritsch, Maikel V. W. van der Velden, Barbara Grohmann-Izay, Gerald Aichinger, P. Noel Barrett, Otfried Kistner, Manuela Koska, Daniel Portsmouth
Publikováno v:
Clinical and Vaccine Immunology. 22:46-55
Studies on candidate pandemic vaccines against avian influenza viruses have focused on H5N1, but viruses of other subtypes, such as A/H9N2, are also considered to have pandemic potential. We investigated the safety and immunogenicity of two immunizat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6fcf223866848b2bfb4f20cb8beeb57
https://doi.org/10.1128/cvi.00275-14
https://doi.org/10.1128/cvi.00275-14
Autor:
John M. Dye, Samantha E. Zak, James F. Barth, Andrew S. Herbert, Majidat A. Muhammad, Kurt Kamrud, Ana I. Kuehne, Mary Kate Hart, Ramon A. Ortiz, Gene G. Olinger, Jennifer L. Groebner, Donald K. Nichols, William D. Pratt, Jonathan F. Smith, John S. Lee, Spencer W. Stonier, Max Custer, Russell R. Bakken, Laura I. Prugar
Publikováno v:
Journal of Virology. 87:4952-4964
There are no vaccines or therapeutics currently approved for the prevention or treatment of ebolavirus infection. Previously, a replicon vaccine based on Venezuelan equine encephalitis virus (VEEV) demonstrated protective efficacy against Marburg vir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2e7f0920bdd4b6b0ad633aec7ec4c72
https://doi.org/10.1128/jvi.03361-12
https://doi.org/10.1128/jvi.03361-12
Autor:
Teri Ann S. Wong, Russell R. Bakken, Mary Kate Hart, Axel T. Lehrer, William D. Pratt, David E. Clements, Michael M. Lieberman, John M. Dye, Tom Humphreys
Publikováno v:
Vaccine
Infections with filoviruses in humans are highly virulent, causing hemorrhagic fevers which result in up to 90% mortality. In addition to natural infections, the ability to use these viruses as bioterrorist weapons is of significant concern. Currentl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e90c9bb7c67501e7785d82329b97a5a3
https://pubmed.ncbi.nlm.nih.gov/28216187
https://pubmed.ncbi.nlm.nih.gov/28216187
Autor:
Gregory Berezuk, Hartmut J. Ehrlich, Julia Singer, Sandor Fritsch, Wael El-Amin, P. Noel Barrett, Otfried Kistner, Gerald Aichinger, Mary Kate Hart, Daniel Portsmouth
Publikováno v:
Vaccine. 30:4377-4386
Background Cell culture technologies have the potential to improve the robustness and flexibility of influenza vaccine supply and to substantially shorten manufacturing timelines. We investigated the safety, immunogenicity and efficacy of a Vero cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::285e9491f7208e55c2a939e5a2d5a2fe
https://doi.org/10.1016/j.vaccine.2011.11.114
https://doi.org/10.1016/j.vaccine.2011.11.114
Autor:
Daniel Portsmouth, Julia Singer, Otfried Kistner, Gerald Aichinger, P. Noel Barrett, Mary Kate Hart, Wael El-Amin, Sandor Fritsch, Gregory Berezuk, Hartmut J. Ehrlich
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
A Vero cell culture–derived seasonal influenza vaccine provides consistently high levels of protection against cell culture–confirmed infection over a complete influenza season. Influenza symptoms are also less severe and of shorter duration in i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d50ce4d837e5ac1c6759f9b36bb6db9c
https://doi.org/10.1093/cid/cir959
https://doi.org/10.1093/cid/cir959
Autor:
Michael D. Parker, Marilyn J. Buckley, Mary Kate Hart, Pamela J. Glass, Vanessa R. Melanson, David Norwood
Publikováno v:
Journal of Virology. 84:12683-12690
Six monoclonal antibodies were isolated that exhibited specificity for a furin cleavage site deletion mutant (V3526) of Venezuelan equine encephalitis virus (VEEV). These antibodies comprise a single competition group and bound the E3 glycoprotein of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce56bd53281f98d8ab35cc8af01988c8
https://doi.org/10.1128/jvi.01345-10
https://doi.org/10.1128/jvi.01345-10
Autor:
Ed Barr, William Mega, Mary Kate Hart, William C. Blackwelder, P.F. Fellows, Robert Sherwood, Winston Lin, Trevor Brasel, Amanda M. Rom, Lou Holland, Justin Hartings, Jeffrey J. Adamovicz, Jessica Price, Stephen R. Morris, Doris Snow
Publikováno v:
Vaccine. 28:7748-7756
Passive transfer models were developed to evaluate the ability of antibodies generated in cynomolgus macaques and humans vaccinated with a recombinant plague vaccine (rF1V) to protect naïve Swiss Webster mice against pneumonic plague. Development of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35a53885ee99f3f6aa84a79c01bd84fd
https://doi.org/10.1016/j.vaccine.2010.09.062
https://doi.org/10.1016/j.vaccine.2010.09.062